20 results match your criteria: "Texas (T.S.A.); Medical Center Haaglanden[Affiliation]"
Diplomate in Medical Laboratory Immunology Certification Examination: A New Chapter for Medical Laboratory Immunology.
Immunohorizons
August 2023
Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
It is indeed a privilege to be an immunologist in what is arguably the golden age of immunology. From astounding advances in fundamental knowledge to groundbreaking immunotherapeutic offerings, immunology has carved out an enviable niche for itself in basic science and clinical medicine. The need and the vital importance of appropriate education, training, and certification in clinical immunology was recognized by the World Health Organization as far back as 1972.
View Article and Find Full Text PDFTransplantation Outcomes with Donor Hearts after Circulatory Death.
N Engl J Med
June 2023
From Duke University Medical Center, Durham, NC (J.N.S., C.B.P., A.D.D., S.C., C.A.M.); Northwestern University (B.S.B., D.T.P.) and the University of Chicago (C.T.S.) - both in Chicago; Vanderbilt University Medical Center, Nashville (A.S., T.A.); University of Wisconsin Hospital and Clinics, Madison (J.W.S.), and the Medical College of Wisconsin, Milwaukee (D.L.J.); the University of California, San Francisco, San Francisco (A.G.F.), the University of California, San Diego, La Jolla (V.P.), Cedars-Sinai Medical Center, Los Angeles (F.E.), and Stanford University Medical Center, Stanford (Y.S.) - all in California; Emory University Hospital, Atlanta (M.D., T.S.A.); Advent Health, Orlando (S.S.), Mayo Clinic, Jacksonville (S.M.P.), and Tampa General Hospital, Tampa (J.D., L.L.) - all in Florida; Yale School of Medicine, New Haven, CT (A.G.); Nebraska Medical Center, Omaha (J.Y.U.); Columbia University Medical Center, New York (K.T.), Montefiore Medical Center, Bronx (D.J.G.), and Westchester Medical Center, Valhalla (M.K.) - all in New York; Minneapolis Heart Institute Foundation (K.M., B.S., B.C.S.) and the University of Minnesota Medical Center (A.W.S.) - both in Minneapolis; Sentara Norfolk General Hospital, Norfolk (J.P.), and Virginia Commonwealth University, Richmond (M.A.Q.) - both in Virginia; Tufts Medical Center (G.S.C.), Brigham and Women's Hospital (H.R.M., M.M.G., M.R.M.), and Massachusetts General Hospital (J.C.M., D.A.D.) - all in Boston; and the University of Texas Southwestern Medical Center, Dallas (M.F.).
Background: Data showing the efficacy and safety of the transplantation of hearts obtained from donors after circulatory death as compared with hearts obtained from donors after brain death are limited.
Methods: We conducted a randomized, noninferiority trial in which adult candidates for heart transplantation were assigned in a 3:1 ratio to receive a heart after the circulatory death of the donor or a heart from a donor after brain death if that heart was available first (circulatory-death group) or to receive only a heart that had been preserved with the use of traditional cold storage after the brain death of the donor (brain-death group). The primary end point was the risk-adjusted survival at 6 months in the as-treated circulatory-death group as compared with the brain-death group.
A saturated map of common genetic variants associated with human height.
Nature
October 2022
Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA.
Article Synopsis
- Common SNPs may account for 40-50% of human height variation, and this study identifies 12,111 SNPs linked to height from a large sample of 5.4 million individuals.
- These SNPs cluster in 7,209 genomic segments, encompassing about 21% of the genome and showing varying densities enriched in relevant genes.
- While these SNPs explain a substantial portion of height variance in European populations (40-45%), their predictive power is lower (10-24%) in other ancestries, suggesting a need for more research to enhance understanding in diverse populations.
Anticytomegalovirus CD4 T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV.
Arterioscler Thromb Vasc Biol
April 2021
Division of Infectious Diseases (C.N.W., S.B., L.M.M., C.M.W., R.G., R.S., S.A.K., S.A.M., J.R.K.), Vanderbilt University Medical Center, Nashville.
[Figure: see text].
View Article and Find Full Text PDFImproving the Diagnosis of Ipsilateral Femoral Neck and Shaft Fractures: A New Imaging Protocol.
J Bone Joint Surg Am
February 2020
Orthopaedic Trauma Service (T.S.A., J.L.G., A.M.C., M.L.R., J.W.M., and S.J.W.) and Department of Radiology (M.K.), McGovern Medical School at UTHealth Houston (N.B.R. and B.E.H.), Houston, Texas.
Background: Despite increased awareness of ipsilateral femoral neck fractures in patients with high-energy femoral shaft fractures and advanced imaging with thin-cut high-resolution computed tomography (CT), failure of diagnosis remains problematic. The purpose of the present study was to determine if the preoperative diagnosis of ipsilateral femoral neck fractures in patients with high-energy femoral shaft fractures can be improved with magnetic resonance imaging (MRI) compared with radiographic and CT imaging.
Methods: In response to delayed diagnoses of femoral neck fractures despite thin-cut high-resolution CT, our institutional imaging protocol for acute, high-energy femoral shaft fractures was altered to include rapid limited-sequence MRI to evaluate for occult femoral neck fractures.
Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study.
PLoS One
August 2017
Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.
An increasing number of genome-wide association (GWA) studies are now using the higher resolution 1000 Genomes Project reference panel (1000G) for imputation, with the expectation that 1000G imputation will lead to the discovery of additional associated loci when compared to HapMap imputation. In order to assess the improvement of 1000G over HapMap imputation in identifying associated loci, we compared the results of GWA studies of circulating fibrinogen based on the two reference panels. Using both HapMap and 1000G imputation we performed a meta-analysis of 22 studies comprising the same 91,953 individuals.
View Article and Find Full Text PDFSeizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
Neuro Oncol
January 2017
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (E.K.A., L.M.D.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neurology, VUmc Cancer Center, Amsterdam, Netherlands (J.C.R.); Department of Family Health, University of Texas Health Science Center, Houston, Texas (T.S.A.); Department of Neuro-Oncology, City of Health and Science Hospital, Torino, Italy (R.R.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/ Brigham and Women's Center, Boston, Massachusetts (P.W.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Leiden University Medical Center, The Hague, Netherlands (J.A.F.K.); Department of Neurosurgery, Wayne State University, Detroit, Michigan (S.M.); Department of Neurosurgery, Kyoto University School of Graduate Medicine, Kyoto, Japan (Y.A.); Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois (A.C.); Department of Epilepsy and Surgery Center, Cleveland Clinic, Cleveland, Ohio (J.G.-M.); Department of Neurology, London Health Sciences Center, London, Ontario, Canada (D.R.M.); Department of Neurosurgery, Saitama Medical University, Saitama, Japan (R.N.); Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan (A.S.); Service Neurologie Mazarin, CHU Pitie-Salpetriere, Paris, France (C.J.V.); Department of Neurology, University of Alabama, Birmingham, Alabama (P.W.); Department of Neuro-Oncology, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands (M.J.v.d.B.).
Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival.
View Article and Find Full Text PDFBiology and management of ependymomas.
Neuro Oncol
July 2016
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (J.W., M.R.G.); Department of Family Health, University of Texas Health Science Center at Houston, Houston, Texas (T.S.A.).
Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by genomic studies based on locations in classic grade II and III ependymomas.
View Article and Find Full Text PDFReport of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Neuro Oncol
March 2016
National Brain Tumor Society, Newton, Massachusetts (J.L.H.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (P.Y.W.); Department of Neuro-Oncology, Johns Hopkins University, Brain Cancer Program, Baltimore, Maryland (J.B.); Center for Cancer Research, Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland (M.R.G.); The University of Texas Health Science Center at Houston, School of Nursing, Department of Family Health, Houston, Texas (T.S.A.).
On October 15, 2014, a workshop was held on the use of clinical outcome assessments in clinical trials for high-grade glioma of the brain. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, the Musella Foundation for Brain Tumor Research and Information, and Accelerate Brain Cancer Cure. It was planned and carried out with participation from the US Food and Drug Administration.
View Article and Find Full Text PDFDetermining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.
Neuro Oncol
March 2016
The University of Texas Health Science Center at Houston and MD Anderson Cancer Center, Houston, Texas (T.S.A.); Patient Advocate, Bryn Mawr, Pennsylvania (A.M.B.); The University of Texas MD Anderson Cancer Center, Houston, Texas (P.D.B.); VU University Medical Center, Amsterdam, Netherlands (M.K.); VU University Medical Center, Amsterdam, and Medical Center Haaglanden, The Hague, Netherlands (M.J.B.T.); Genentech, South San Francisco, California (C.T.-O.).
Patients with primary brain tumors such as malignant gliomas are highly symptomatic, often from the time of diagnosis. Signs and symptoms (signs/symptoms) can cause functional limitations that often worsen over the disease trajectory and may impact patient quality of life. It is recognized that standard measurements of tumor response do not adequately measure this impact or the impact that a therapy may have to mitigate these signs/symptoms and potentially have clinical benefit.
View Article and Find Full Text PDFEpilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.
Neuro Oncol
June 2016
Department of Family Health, University of Texas Health Science Center at Houston, Houston, Texas (T.S.A.); Edinburgh Centre for Neuro-Oncology, Edinburgh, UK (R.G.); Neuro-Oncology Branch, National Cancer Institute and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (M.R.G.); Division of EEG and Epilepsy, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts (J.W.L.); Center for Neuro-Oncology, Dana-Farber Cancer Institute; Division of Cancer Neurology, Department of Neurology, Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts (A.D.N.).
Seizures are a well-recognized symptom of primary brain tumors, and anticonvulsant use is common. This paper provides an overview of epilepsy and the use of anticonvulsants in glioma patients. Overall incidence and mechanisms of epileptogenesis are reviewed.
View Article and Find Full Text PDFThe symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms.
Neuro Oncol
February 2016
University of Texas Health Science Center at Houston, Houston, Texas (T.S.A., H.L.); The University of Texas MD Anderson Cancer Center, Houston, Texas (T.S.A., E.V.-B., A.A.A., M.R.G., T.M.).
Background: A set of symptoms common across cancers has been proposed to enhance quality of care and clinical research in solid tumor patients. Using data from several clinical studies, this study evaluated these symptoms in primary brain tumor patients.
Methods: Symptom report data using the MD Anderson Symptom Instrument -Brain Tumor (MDASI-BT) from 621 patients enrolled in 8 clinical studies was used.
Hope and mood changes throughout the primary brain tumor illness trajectory.
Neuro Oncol
January 2016
Department of Family Health, University of Texas Health Science Center School of Nursing, Houston, Texas (A.A.A.); Department of Family Health, The University of California, San Francisco, California (L.L.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (E.V.-B., T.S.A.); Department of Neuro-Oncology, National Institutes of Health, Bethesda, Maryland (M.R.G.); Department of Family Health, University of Texas Health Science Center School of Nursing, Houston, Texas (T.S.A.).
Background: The ambiguity of defining hope impacts the level of readiness faced by health care professionals treating patients with glioma, a disease with unpredictable outcomes. This study describes the report of hope and the relationship between hope and mood in adult brain tumor patients at various points in the illness trajectory.
Methods: This was a cross-sectional study with data collection including use of the Herth Hope Index (HHI), the Profile of Mood States-Short Form (POMS-SF), and clinical information.
Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials.
Neurooncol Pract
March 2015
VU University Medical Center, Department of Neurology , Amsterdam , Netherlands (L.D., M.J.B.T.); The University of Texas Health Science Center at Houston, School of Nursing, Department of Family Health , Houston, Texas (T.S.A.); The University of Texas M.D. Anderson Cancer Center, Department of Neuro-Oncology, Houston, Texas (T.S.A.); Medical Center Haaglanden, Department of Neurology, The Hague , Netherlands (M.J.B.T.).
Primary brain tumors and posterior reversible encephalopathy syndrome.
Neurooncol Pract
December 2014
Department of Neuro-Oncology , The University of Texas MD Anderson Cancer Center, Houston, Texas (C.K.-M., D.C., T.S.A., M.R.G.); Department of Family Health , The University of Texas Health Science Center School of Nursing , Houston, Texas (T.S.A.); Department of Pathology , The University of Texas MD Anderson Cancer Center, Houston, Texas (A.O.).
Background: Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic encephalopathic state associated with reversible cerebral vasogenic edema. It is an increasingly recognized occurrence in the oncology population. However, it is very uncommon in patients with primary brain tumors (PBTs).
View Article and Find Full Text PDFPersonal health records, symptoms, uncertainty, and mood in brain tumor patients.
Neurooncol Pract
June 2014
Department of Family Health , The University of Texas Health Science Center at Houston, School of Nursing , Houston, Texas (J.E.C., L.L., T.S.A.); Department of Neuro-Oncology , The University of Texas MD Anderson Cancer Center, Houston, Texas (T.S.A., A.A.A., E.V.B., M.R.G.); Department of Nursing Systems , The University of Texas Health Science Center at Houston, School of Nursing, Houston, Texas (G.L.W., N.S.P.).
Background: The advantages of patient access to the electronic medical record (EMR) through integrated personal health records (PHR) may be substantial, and foremost is the enhanced information flow between patient and practitioner. Because this is an emerging technology, the actualized benefits to complex patient groups remain largely unknown. MD Anderson Cancer Center provides web-based PHR portal access to the EMR including clinic notes, MRI results, and pathology reports.
View Article and Find Full Text PDFThe relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic.
Neuro Oncol
August 2015
University of Texas Health Science Center, Houston, Texas (T.S.A.); M.D. Anderson Cancer Center, Houston, Texas (T.S.A., Y.Y., J.W., A.A.A., E.V.-B., P.D.B.); National Institutes of Health, Bethesda, Maryland (M.R.G.); University of Sydney Concord Repatriation General Hospital, Concord, New South Wales, Australia (J.V.); Department of Radiation Oncology, University of Toronto/University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada (C.C.).
Background: Corticosteroids can have many side effects that impact the patient's quality of life and functional status. The Dexamethasone Symptom Questionnaire-Chronic (DSQ-C) was developed to report corticosteroid side effects. This study's objective was to evaluate the utility of the DSQ-C and report associated signs and symptoms in brain tumor patients.
View Article and Find Full Text PDFClinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
Neuro Oncol
March 2015
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California (G.D.); Departments of Neurology and Medicine (Medical Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology & Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.); Department of Neurology, Stanford University & Lucile Packard Children's Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.); Department of Family Health, School of Nursing, The University of Texas Health Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
Background: Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution.
Methods: Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed.
Pregnancy and glial brain tumors.
Neuro Oncol
September 2014
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.Y.-K., J.F.d.G., M.D.A., C.A.C., M.R.G., T.S.A.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas (D.L., J.W., Y.Y.); Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.).
Background: Improvements in brain tumor treatments have led to an increase in the number of young women with brain tumors who are now considering pregnancy. The aim of this study is to evaluate the influence of pregnancy on brain tumor biology.
Methods: In this institutional review board-approved retrospective study, we searched the institution's database for patients with glial brain tumors who were pregnant at the time of diagnosis or became pregnant during the course of their illness.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med
February 2014
From the University of Texas M.D. Anderson Cancer Center (M.R.G., T.S.A., J.S.W., P.D.B., I.W.T.-L., E.P.S., K.D.A.) and the University of Texas Health Science Center School of Nursing (T.S.A.), Houston; American College of Radiology (J.J.D., S.P., M.W.) and Thomas Jefferson University (M.W.-W.) - both in Philadelphia; the University of Chicago, Chicago (J.J.D.); Tel-Aviv Medical Center, Tel Aviv, Israel (D.T.B.); Cleveland Clinic, Cleveland (M.A.V.); the University of Utah, Salt Lake City (H.C.); Ohio State University, Columbus (A.C.); University of Wisconsin, Madison (R.J.); Mayo Clinic, Jacksonville, FL (K.A.J.); University of Virginia, Charlottesville (D.S.); Southeast Cancer Control Consortium, Winston-Salem, NC (V.W.S.); Barrow Neurologic Institute, Phoenix, AZ (D.G.B.); Emory University, Atlanta (W.J.C.); and the University of Maryland, Baltimore (M.P.M.).
Background: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known.
View Article and Find Full Text PDF